|
AU2003229953A1
(en)
|
2002-04-30 |
2003-11-17 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
BRPI0408284B8
(pt)
*
|
2003-03-12 |
2021-05-25 |
Kudos Pharm Ltd |
compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
|
|
GB0317466D0
(en)
*
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
KR20060037409A
(ko)
|
2003-07-30 |
2006-05-03 |
제논 파마슈티칼스 인크. |
피페라진 유도체 및 그의 치료제로서의 용도
|
|
CN103275058B
(zh)
|
2003-08-06 |
2016-02-24 |
西诺米克斯公司 |
调味剂、味道调节剂、促味剂、味觉增强剂、鲜味剂或甜味剂和/或增强剂及其用途
|
|
GB0324159D0
(en)
|
2003-10-15 |
2003-11-19 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2005053662A1
(en)
*
|
2003-12-01 |
2005-06-16 |
Kudos Pharmaceuticals Limited |
Dna damage repair inhibitors for treatment of cancer
|
|
GB0419072D0
(en)
|
2004-08-26 |
2004-09-29 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
MX2007002318A
(es)
*
|
2004-08-26 |
2007-04-17 |
Kudos Pharm Ltd |
Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
|
|
EP1645556A1
(en)
*
|
2004-10-07 |
2006-04-12 |
Boehringer Ingelheim International GmbH |
Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
|
|
KR101340859B1
(ko)
*
|
2005-02-04 |
2013-12-13 |
세노믹스, 인코포레이티드 |
연결형 헤테로 아릴 잔기를 포함한 화합물, 및 식용조성물을 위한 신규의 우마미 향미 개선제, 맛 촉진물질 및맛 향상제로서의 그의 용도
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
TW200715993A
(en)
|
2005-06-15 |
2007-05-01 |
Senomyx Inc |
Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
|
|
ATE455117T1
(de)
*
|
2005-09-23 |
2010-01-15 |
Equispharm Co Ltd |
5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
|
|
GB0521373D0
(en)
|
2005-10-20 |
2005-11-30 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
|
EP3235811B1
(en)
|
2006-04-21 |
2018-07-25 |
Senomyx, Inc. |
Process of preparing oxalamides
|
|
CA2652167A1
(en)
*
|
2006-05-31 |
2007-12-06 |
Philip Jones |
Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
|
|
GB0610680D0
(en)
*
|
2006-05-31 |
2006-07-12 |
Istituto Di Ricerche D Biolog |
Therapeutic compounds
|
|
US20090281086A1
(en)
*
|
2006-06-15 |
2009-11-12 |
Kudos Pharmaceuticals Limited |
2 -oxyheteroarylamide derivatives as parp inhibitors
|
|
WO2008020180A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Kudos Pharmaceuticals Limited |
Methods of increasing the sensitivity of cancer cells to dna damage
|
|
AU2013201880B2
(en)
*
|
2006-10-17 |
2015-06-25 |
Kudos Pharmaceuticals Limited |
Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
|
|
UY30639A1
(es)
*
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
PE20081229A1
(es)
*
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
DK2120579T3
(da)
*
|
2006-12-28 |
2014-02-03 |
Abbvie Inc |
Inhibitorer af poly(ADP-ripose)polymerase
|
|
BRPI0811059A2
(pt)
*
|
2007-05-25 |
2017-05-09 |
Astrazeneca Ab |
combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
|
|
CA2687931C
(en)
|
2007-05-31 |
2016-05-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists and uses thereof
|
|
US20090023727A1
(en)
*
|
2007-07-05 |
2009-01-22 |
Muhammad Hashim Javaid |
Phthalazinone derivatives
|
|
GB0716532D0
(en)
*
|
2007-08-24 |
2007-10-03 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
PL2209375T3
(pl)
|
2007-10-03 |
2014-12-31 |
Eisai Inc |
Związki, kompozycje i metody stosowania inhibitorów PARP
|
|
JP5593229B2
(ja)
*
|
2007-10-17 |
2014-09-17 |
クドス ファーマシューティカルズ リミテッド |
４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン
|
|
MX2010005070A
(es)
*
|
2007-11-15 |
2010-05-24 |
Angeletti P Ist Richerche Bio |
Derivados de piridazinona como inhibidores de parp.
|
|
CL2008003553A1
(es)
*
|
2007-12-05 |
2009-11-27 |
Grindeks Jsc |
Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
|
|
BRPI0820701A2
(pt)
*
|
2007-12-11 |
2015-06-16 |
Cytopathfinder Inc |
Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
|
|
AR070221A1
(es)
*
|
2008-01-23 |
2010-03-25 |
Astrazeneca Ab |
Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
|
|
EP2767537B1
(en)
|
2008-08-06 |
2017-04-12 |
Medivation Technologies, Inc. |
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
|
|
ES2598178T5
(es)
*
|
2008-10-07 |
2023-12-26 |
Kudos Pharm Ltd |
Formulación farmacéutica 514
|
|
CN102256963B
(zh)
|
2008-12-19 |
2014-06-11 |
贝林格尔.英格海姆国际有限公司 |
作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
|
|
UY32790A
(es)
*
|
2009-07-15 |
2011-02-28 |
Astrazeneca Ab |
Compuesto de ftalazinona
|
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
|
WO2011058367A2
(en)
|
2009-11-13 |
2011-05-19 |
Astrazeneca Ab |
Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
|
|
EP2322658A1
(en)
|
2009-11-13 |
2011-05-18 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of breast cancer aggressiveness and genetic instability
|
|
MX346393B
(es)
|
2009-12-17 |
2017-03-17 |
Centrexion Therapeutics Corp |
Nuevos antagonistas del receptor ccr2 y usos de los mismo.
|
|
US8541403B2
(en)
|
2010-02-03 |
2013-09-24 |
Biomarin Pharmaceutical Inc. |
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
|
|
DK2533640T3
(en)
*
|
2010-02-08 |
2017-01-23 |
Medivation Technologies Inc |
METHODS OF SYNTHESIS OF DIHYDROPYRIDOPHTHALAZINE DERIVATIVES
|
|
WO2011141477A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
JP2013526507A
(ja)
|
2010-05-12 |
2013-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
|
|
WO2011144501A1
(en)
|
2010-05-17 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 antagonists and uses thereof
|
|
WO2011147772A1
(en)
|
2010-05-25 |
2011-12-01 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists
|
|
US8962656B2
(en)
|
2010-06-01 |
2015-02-24 |
Boehringer Ingelheim International Gmbh |
CCR2 antagonists
|
|
US8871765B2
(en)
|
2010-07-27 |
2014-10-28 |
Cadila Healthcare Limited |
Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
|
|
CN102372716A
(zh)
*
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
TWI557123B
(zh)
*
|
2010-10-21 |
2016-11-11 |
梅迪維新技術公司 |
結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
|
|
WO2012071684A1
(en)
|
2010-12-02 |
2012-06-07 |
Shanghai De Novo Pharmatech Co Ltd. |
Heterocyclic derivates，preparation processes and medical uses thereof
|
|
EP2686305B1
(en)
*
|
2011-03-14 |
2020-09-16 |
Impact Therapeutics, Inc. |
Quinazolinediones and their use
|
|
US20140051737A1
(en)
*
|
2011-05-10 |
2014-02-20 |
Universite Laval |
Methods for the treatment and diagnostic of pulmonary arterial hypertension
|
|
CN103827314A
(zh)
|
2011-05-18 |
2014-05-28 |
国家科学研究中心 |
用于诊断癌侵袭性和遗传不稳定性的标记
|
|
EP2714703B1
(en)
|
2011-05-31 |
2021-03-10 |
Newgen Therapeutics, Inc. |
Tricyclic inhibitors of poly(adp-ribose)polymerase
|
|
WO2013010839A1
(en)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Novel and selective ccr2 antagonists
|
|
SG10201605814QA
(en)
|
2011-07-22 |
2016-09-29 |
Pacylex Pharmaceuticals Inc |
Synthetic lethality and the treatment of cancer
|
|
CN103130723B
(zh)
*
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
CN104145030B
(zh)
|
2012-01-05 |
2016-10-12 |
国家科学研究中心 |
用于诊断肺癌侵袭性和遗传不稳定性的标记
|
|
CN102964354B
(zh)
*
|
2012-11-16 |
2014-08-13 |
江苏先声药业有限公司 |
一类噻吩并咪唑衍生物及其应用
|
|
WO2014102817A1
(en)
|
2012-12-31 |
2014-07-03 |
Cadila Healthcare Limited |
Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
|
|
US9783529B2
(en)
|
2013-03-13 |
2017-10-10 |
Flatley Discovery Lab, Llc |
Pyridazinone compounds and methods for the treatment of cystic fibrosis
|
|
EP2970121B1
(en)
*
|
2013-03-15 |
2017-12-13 |
Araxes Pharma LLC |
Covalent inhibitors of kras g12c
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2015014442A1
(en)
*
|
2013-07-31 |
2015-02-05 |
Merck Patent Gmbh |
Oxoquinazolinyl-butanamide derivatives
|
|
PT3030554T
(pt)
*
|
2013-08-07 |
2018-05-28 |
Merck Patent Gmbh |
Derivados de ureia de piperidina
|
|
KR101670126B1
(ko)
|
2013-09-13 |
2016-10-27 |
일동제약(주) |
신규 프탈라지논 유도체 및 그 제조방법
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
CN105985294B
(zh)
*
|
2015-02-11 |
2020-12-25 |
四川科伦药物研究院有限公司 |
一种奥拉帕尼的制备方法
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
CN106146492A
(zh)
*
|
2015-04-17 |
2016-11-23 |
上海汇伦生命科技有限公司 |
杂环并咪唑类化合物、其药物组合物及其制备方法和用途
|
|
KR20180017013A
(ko)
|
2015-05-06 |
2018-02-20 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
K-Ras 조절제
|
|
EP3298005B1
(en)
|
2015-05-21 |
2024-01-24 |
The Regents of The University of California |
Anti-cancer compounds
|
|
AU2016287584B2
(en)
|
2015-07-02 |
2020-03-26 |
Centrexion Therapeutics Corporation |
(4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
|
|
PL3325662T3
(pl)
|
2015-07-17 |
2024-02-26 |
Pacylex Pharmaceuticals Inc. |
Wyciszenie epigenetyczne nmt2
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2879434T3
(es)
|
2015-07-23 |
2021-11-22 |
Inst Curie |
Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
CN106554316B
(zh)
*
|
2015-09-28 |
2019-03-08 |
上海医药集团股份有限公司 |
一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
WO2017087235A1
(en)
*
|
2015-11-20 |
2017-05-26 |
Senhwa Biosciences, Inc. |
Combination therapy of tetracyclic quinolone analogs for treating cancer
|
|
CZ201682A3
(cs)
|
2016-02-15 |
2017-08-23 |
Zentiva, K.S. |
Solvatované krystalické formy olaparibu, jejich příprava a použití
|
|
WO2017191562A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Alembic Pharmaceuticals Limited |
Process for the preparation of olaparib and polymorphs thereof
|
|
MX387726B
(es)
|
2016-06-24 |
2025-03-18 |
Univ California |
Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
|
|
CZ2016391A3
(cs)
|
2016-06-29 |
2018-01-10 |
Zentiva, K.S. |
Farmaceutická formulace olaparibu
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018038680A1
(en)
*
|
2016-08-24 |
2018-03-01 |
Scinopharm Taiwan, Ltd. |
Processes for preparing olaparib
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
CN107955001A
(zh)
|
2016-10-14 |
2018-04-24 |
上海汇伦生命科技有限公司 |
抗肿瘤杂环并咪唑类化合物的药用盐
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
CN110785414A
(zh)
|
2017-04-20 |
2020-02-11 |
加利福尼亚大学董事会 |
K-Ras调节剂
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
CA3031777A1
(en)
|
2018-01-31 |
2019-07-31 |
Apotex Inc. |
Crystalline form of olaparib
|
|
CN112334133A
(zh)
|
2018-02-15 |
2021-02-05 |
生华生物科技股份有限公司 |
喹诺酮类似物及其盐、组合物及其使用方法
|
|
WO2019169156A1
(en)
*
|
2018-02-28 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
|
|
US20200407720A1
(en)
|
2018-03-13 |
2020-12-31 |
Onxeo |
A dbait molecule against acquired resistance in the treatment of cancer
|
|
GB201804924D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Univ Oxford Innovation Ltd |
Radiolabelled compound
|
|
EP3778590A4
(en)
|
2018-04-09 |
2021-12-22 |
ShanghaiTech University |
ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
|
|
CN112566666A
(zh)
*
|
2018-05-14 |
2021-03-26 |
努瓦申生物公司 |
靶向抗癌核激素受体的化合物
|
|
CN108558773A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种奥拉帕尼药物中间体的制备方法
|
|
CA3107168A1
(en)
|
2018-08-01 |
2020-02-06 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
JP2022532342A
(ja)
|
2019-05-14 |
2022-07-14 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
TWI837403B
(zh)
|
2019-07-19 |
2024-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
CN112321566B
(zh)
|
2019-08-05 |
2022-06-10 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
TW202131930A
(zh)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
WO2021141980A1
(en)
*
|
2020-01-07 |
2021-07-15 |
Fan Wu |
Combination cancer therapy using chk inhibitor
|
|
IL294399A
(en)
|
2020-01-09 |
2022-08-01 |
Astrazeneca Ab |
Combination therapy for treating cancer
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
EP4112049A4
(en)
*
|
2020-02-24 |
2024-07-24 |
Fukang (Shanghai) Health Technology Co., Ltd. |
ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR
|
|
CA3176219A1
(en)
|
2020-04-21 |
2021-10-28 |
Kunhee LEE |
Crystalline forms of phthalazinone compound
|
|
JP7626783B2
(ja)
|
2020-04-21 |
2025-02-07 |
アイディーエンス カンパニー リミテッド |
フタラジノン誘導体及びその中間体を調製するプロセス
|
|
KR20230002487A
(ko)
|
2020-04-28 |
2023-01-05 |
리젠 파마슈티컬스 아게 |
폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
|
|
CN111592522B
(zh)
*
|
2020-06-17 |
2022-09-09 |
郑州大学 |
一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
|
|
US11795158B2
(en)
|
2020-06-25 |
2023-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
JP7453475B2
(ja)
|
2020-09-16 |
2024-03-19 |
ナフォーミックス テクノロジーズ リミテッド |
オラパリブシュウ酸共結晶及びその医薬的使用
|
|
AU2021356762A1
(en)
|
2020-10-09 |
2023-05-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
US12059419B2
(en)
|
2020-10-16 |
2024-08-13 |
Idience Co., Ltd. |
Pharmaceutical composition comprising phthalazinone derivatives
|
|
WO2022090938A1
(en)
|
2020-10-31 |
2022-05-05 |
Rhizen Pharmaceuticals Ag |
Phthalazinone derivatives useful as parp inhibitors
|
|
CN112500379B
(zh)
*
|
2020-12-23 |
2024-01-23 |
南京方生和医药科技有限公司 |
一种奥拉帕利中间体及奥拉帕利的制备方法
|
|
TW202304928A
(zh)
|
2021-03-23 |
2023-02-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
CN113024516B
(zh)
*
|
2021-03-29 |
2022-05-17 |
中国药科大学 |
双靶点parp/ezh2抑制剂、制备方法及用途
|
|
BR112023020615A2
(pt)
|
2021-04-08 |
2023-12-19 |
Incozen Therapeutics Pvt Ltd |
Inibidores de poli(adp-ribose) polimerase
|
|
US12006314B2
(en)
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
JP2024518509A
(ja)
|
2021-05-18 |
2024-05-01 |
オンコニック セラピューティクス インコーポレイテッド |
Ｐａｒｐ阻害剤抵抗性癌治療剤
|
|
JP2024520142A
(ja)
|
2021-06-02 |
2024-05-21 |
アストラゼネカ・アクチエボラーグ |
乳癌を処置する方法
|
|
EP4384501A4
(en)
|
2021-08-09 |
2025-01-22 |
Glenmark Life Sciences Limited |
Process for the preparation of olaparib, and crystalline form thereof
|
|
KR102645122B1
(ko)
*
|
2021-08-25 |
2024-03-07 |
주식회사 보령 |
올라파립의 제조방법
|
|
CN120309514A
(zh)
*
|
2021-09-15 |
2025-07-15 |
上海博邦医药科技有限公司 |
一种奥拉帕尼中间体的制备方法
|
|
JP2024543371A
(ja)
|
2021-11-10 |
2024-11-21 |
ナフォーミックス テクノロジーズ リミテッド |
オラパリブヒドロキシ安息香酸共結晶及びその医薬的使用
|
|
CN118414173A
(zh)
|
2021-11-18 |
2024-07-30 |
阿斯利康(英国)有限公司 |
抗体-药物缀合物和parp1选择性抑制剂的组合
|
|
JP2025503465A
(ja)
|
2021-12-21 |
2025-02-04 |
アストラゼネカ・アクチエボラーグ |
脳腫瘍及び神経芽腫を処置する方法
|
|
KR102776660B1
(ko)
*
|
2022-01-25 |
2025-03-04 |
재단법인 한국파스퇴르연구소 |
벤조다이옥세인 유도체 화합물 및 이의 의약 용도
|
|
IL314798A
(en)
|
2022-02-15 |
2024-10-01 |
Astrazeneca Ab |
Prostate cancer treatment methods
|
|
KR20250165438A
(ko)
|
2023-03-31 |
2025-11-25 |
아스트라제네카 아베 |
Azd5305의 투여 레지먼
|
|
WO2024246835A1
(en)
|
2023-05-31 |
2024-12-05 |
Astrazeneca Ab |
Methods, compositions, and combinations for the treatment of ovarian cancer
|
|
CN121398822A
(zh)
|
2023-06-21 |
2026-01-23 |
四方生物科学有限公司 |
用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
|
|
CN119488588A
(zh)
|
2023-08-17 |
2025-02-21 |
阿斯利康(瑞典)有限公司 |
用于治疗子宫内膜癌的方法、组合物和组合
|
|
TW202535479A
(zh)
|
2023-12-05 |
2025-09-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
|
|
TW202545525A
(zh)
|
2024-01-19 |
2025-12-01 |
瑞典商阿斯特捷利康公司 |
包含ａｚｄ５３０５之藥物組成物
|
|
WO2026013152A1
(en)
|
2024-07-09 |
2026-01-15 |
Stada Arzneimittel Ag |
Pharmaceutical composition comprising olaparib
|
|
EP4682140A1
(en)
|
2024-07-17 |
2026-01-21 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Improved process for the preparation of olaparib
|